Dr. Planchard on Dabrafenib/Trametinib Combo in Advanced NSCLC
June 15th 2016
David Planchard, MD, PhD, Department of Medical Oncology, Thoracic Unit, Institut Gustave Roussy, discusses a phase II trial examining the combination of dabrafenib and trametinib in pretreated patients with BRAF V600E-mutant advanced non–small cell lung cancer (NSCLC).